512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies
R Aggarwal, S Umetsu, M Dhawan… - Annals of …, 2021 - annalsofoncology.org
Background Loss of ARID1A leads to increased reliance on ATR (Ataxia Telangiectasia and
Rad3 Related) kinase. ATR inhibition induces synthetic lethality in ARID1A-deficient
preclinical models. We evaluated ceralasertib, an ATR inhibitor, alone and in combination
with Olaparib, in patients harboring ARID1A-deficient and-intact solid tumors, respectively.
Methods Patients (pts) with advanced solid tumor malignancies were enrolled. ARID1A
deficiency was defined as absence of tumor expression of its gene product BAF250a by …
Rad3 Related) kinase. ATR inhibition induces synthetic lethality in ARID1A-deficient
preclinical models. We evaluated ceralasertib, an ATR inhibitor, alone and in combination
with Olaparib, in patients harboring ARID1A-deficient and-intact solid tumors, respectively.
Methods Patients (pts) with advanced solid tumor malignancies were enrolled. ARID1A
deficiency was defined as absence of tumor expression of its gene product BAF250a by …
